Valbiotis: Largely Successful Capital Increase Through a Private Placement Totaling 15 Million Euros
Gross amount of the capital increase: 15 M€.
Market capitalization: 79 M€, after issuance of 1,930,000 New Shares at a unit price of 7.80 €, representing a 5.1% discount.
Funding secured until first semester 2024.
A sustainably secure financial situation that does not include milestones payments and potential royalties resulting from the partnership with Nestlé Health Science as well as additional revenues associated with the signing of any new partnership.
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 ALVAL, PEA-PME eligible), a Research Development company committed to scientific innovation for the treatment and prevention of metabolic diseases, today announces the large successful capital increase through a private placement open to certain categories of beneficiaries launched the previous day and achieved using an accelerated bookbuilding process. Given
Valbiotis Launches a Capital Increase Through a Private Placement
Regulatory News:
Valbiotis (Paris:ALVAL) (FR0013254851 ALVAL, PEA-PME eligible), a Research Development company committed to scientific innovation for preventing and combating metabolic diseases, today announces the launch of a capital increase within the context of a private placement through an accelerated bookbuilding process for an amount of approximately 12 million euros. This capital increase, with the removal of shareholders preferential subscription rights in favor of a category of persons, will be reserved exclusively for qualified investors as referred to in article 2(e) of Regulation (EU) 2017/1129 of June 14, 2017.
Reasons for the offer
The net proceeds of the capital increase are intended primarily to finance the acceleration of the development of TOTUM•854 (prevention of arterial hypertension) with the launch of three clinical trials at the end of this year including a Phase II/III clinical tria
VALBIOTIS Releases Its 2020 Annual Results
2020 highlights and results
Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with clinically proven metabolic health benefits in prediabetic subjects.
Launch of REVERSE-IT, a global pivotal Phase II/III clinical trial of TOTUM-63 for reducing Type 2 Diabetes risk factors.
New milestones achieved with TOTUM-070, a plant-based active substance for lowering LDL-cholesterol, a risk factor for cardiovascular disease.
€14.6m in cash as at December 31, 2020.
Post-balance sheet events and outlook
Important milestones are expected to be reached in the development of TOTUM-070 (reduction in blood LDL-cholesterol levels).
VALBIOTIS: 2021 Financial Communication Calendar
Regulatory News:
VALBIOTIS (Paris:ALVAL) (FR0013254851 ALVAL eligible for the PEA/SME), a Research Development company committed to scientific innovation for preventing and combating metabolic diseases, today presents its 2021 financial communication calendar.
March, 17: Annual Report (after market closing)
May, 27: General Meeting (terms of participation to be specified later)
September, 30: Half-year Report (after market closing)
ABOUT VALBIOTIS
VALBIOTIS is a Research Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.